Date: 2012-06-17
Type of information: Presentation of results at a congress
phase: 2
Announcement: oral presentation held by Prof. Dr. Hervé Dombret, Hospital Saint Louis, Paris (France) at the 17th Annual Meeting of European Hematology Association (EHA) in Amsterdam (The Netherlands).
Company: Erytech Pharma (France)
Product: erythrocyte encapsulated asparaginase
Action mechanism:
Disease: adult lymphoblastic leukemia (ALL)
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: Thirty patients over 55-years old, newly diagnosed with acute lymphoblastic leukemia (ALL) were included in this Phase II trial. The patients received different doses of erythrocyte encapsulated asparaginase in combination with the chemotherapy recommended by the European Working group for Adult Lymphoblastic Leukemia (EWALL). Asparaginase is a major and mainstay drug to treat ALL, but current formulations are not recommended in induction therapy for these older patients who are particularly frail for toxicity reasons.
Erythrocyte encapsulated Asparaginase introduced in first line induction therapy showed a good safety profile even in the elderly patients and is efficient for asparagine depletion.
At the optimal dose (100IU/Kg), 91% of the patients at the end of induction therapy reached a complete remission and the median overall survival was 15.6 months. The enrollment of the patients was finished 2 months in anticipation to the expectations. The study was performed in close collaboration to the cooperative group GRAALL (Group for Research in Adult Acute Lymphoblastic Leukemia).
